Sugi Predict

Sugi Predict / Compounds / SCHEMBL1707141

SCHEMBL1707141

SCHEMBL1707141

COc1c(Br)cccc1[N+](=O)[O-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ TSHR P16473 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ GPR35 Q9HC97 1/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.42
▸ MAPT P10636 3/20 0.42
▸ TUBB4A P04350 1/20 0.42
▸ TUBB P07437 1/20 0.42
▸ TUBA3C P0DPH7 1/20 0.42
▸ TUBA1B P68363 1/20 0.42
▸ TUBA4A P68366 1/20 0.42
▸ TUBB4B P68371 1/20 0.42
▸ TUBB3 Q13509 1/20 0.42
▸ TUBB2A Q13885 1/20 0.42
▸ TUBB8 Q3ZCM7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079450 1.00 TDP1 (0.52) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL29739945 0.88 TDP1 (0.44) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL358770 0.86 TDP1 (0.61) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL29501004 0.83 ALDH1A1 (0.44) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL25161887 0.81 TDP1 (0.55) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL2088309 0.81 TDP1 (0.71) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL31119224 0.81 TDP1 (0.71) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL31119225 0.81 TDP1 (0.71) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL15283229 0.81 TDP1 (0.44) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2
SCHEMBL26627310 0.81 ALDH1A1 (0.50) TDP1ALDH1A1L3MBTL1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751276-A Preparation method of 3-bromo-2-methoxyaniline 合肥凡华医药发展有限公司 2025-04-04 — — CN claimed
CN-119638575-A Method for preparing key intermediate of eltrombopag by one-pot method 浙江国邦药业有限公司 2025-03-18 — — CN claimed
CN-104592033-A Synthetic method of promacta key intermediate HANGZHOU HEZE PHARMACEUTICAL TECHNOLOGY CO LTD 2015-05-06 — — CN claimed
CN-122067649-A Reaction optimization method based on double-view contrast learning and double-layer attention 浙江大学 2026-05-19 — — CN disclosed
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 — — EP disclosed
EP-4615832-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS Bristol-Myers Squibb Company (US) 2025-09-17 — — EP disclosed
US-20250257051-A1 SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS 1910 GENETICS INC (US) 2025-08-14 — — US disclosed
US-20250243193-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES SYNGENE INTERNATIONAL LIMITED (IN) 2025-07-31 — — US disclosed
CN-120152968-A Substituted heterocyclic compounds 百时美施贵宝公司 2025-06-13 — — CN disclosed
US-20250163004-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2025-05-22 — — US disclosed
EP-3848370-B1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2025-05-07 — — EP disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 — — US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 — — EP disclosed
EP-1370252-A1 THROMBOPOIETIN MIMETICS SmithKline Beecham Corporation (US) 2003-12-17 — — EP disclosed
EP-1351979-A1 REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS SmithKline Beecham Corporation (US) 2003-10-15 — — EP disclosed
CN-1444477-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2003-09-24 — — CN disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 — — EP disclosed
WO-2002085343-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-31 — — WO disclosed
WO-2002057300-A1 REGULATED ACTIVATION OF CELL-MEMBRANE RECEPTORS BY METAL-CHELATING AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2002-07-25 — — WO disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163004-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS TYK2, JAK2, STAT3 TDP1 455/4885ALDH1A1 3621/4885L3MBTL1 4299/4885
US-20250243193-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES IFNG, IFNAR1, TYK2 TDP1 2019/4885ALDH1A1 4349/4885L3MBTL1 3517/4885
US-20250257051-A1 SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS TYK2, PDXK, JAK1 TDP1 213/4885ALDH1A1 3146/4885L3MBTL1 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.